Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses Meeting Abstract
| Authors: | Chan, J.; Geyer, S.; Zemla, T.; Knopp, M. V.; Behr, S. C.; Pulsipher, S.; Acoba, J.; Shergill, A.; Wolin, E. M.; Halfdanarson, T. R.; Konda, B.; Trikalinos, N.; Shaheen, S.; Vijayvergia, N.; Dasari, N. A.; Strosberg, J.; Kohn, E. C.; Kulke, M.; O'Reilly, E. M.; Meyerhardt, J. |
| Abstract Title: | Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S749 |
| Language: | English |
| ACCESSION: | WOS:001326612901444 |
| DOI: | 10.1016/j.annonc.2024.08.1200 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1141O -- Source: Wos |
